Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
201.86 USD   +3.75%
11/23BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022
AQ
11/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/22BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA«áVersus IMBRUVICA«áin Late-Breaking Oral Session at ASH 2022
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BEIGENE, LTD.
11/23BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
AQ
11/22BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
BU
11/22Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for B..
CI
11/21Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee
CI
11/18BeiGene Receives European Commission Approval for BRUKINSA for the Treatment of Adults ..
AQ
11/18European Commission Approves BeiGene's Chronic Lymphocytic Leukemia Treatment; Shares S..
MT
11/17BeiGene's Brukinsa Drug Wins EU Nod For Chronic Lymphocytic Leukemia
MT
11/17Insider Sell: Beigene
MT
11/17Insider Sell: Beigene
MT
11/17BeiGene Says European Commission Approves Brukinsa as Treatment for Chronic Lymphocytic..
MT
11/17BeiGene Receives European Commission Approval for BRUKINSA« (zanubrutinib) for the Trea..
BU
11/17BeiGene Receives European Commission Approval for Brukinsa« (Zanubrutinib) for the Trea..
CI
11/15BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental H..
BU
11/10BeiGene's Brukinsa Secures Brazilian Approvals for Certain Cancers; Shares Rise
MT
11/10SVB Securities Adjusts Price Target on BeiGene to $210 From $200, Maintains Outperform ..
MT
More most relevant news
All news about BEIGENE, LTD.
11/23BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
AQ
11/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/22BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
BU
11/22Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for B..
CI
11/21Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee
CI
11/18BeiGene Receives European Commission Approval for BRUKINSA for the Treatment of Adults ..
AQ
11/18European Commission Approves BeiGene's Chronic Lymphocytic Leukemia Treatment; Shares S..
MT
11/17BeiGene's Brukinsa Drug Wins EU Nod For Chronic Lymphocytic Leukemia
MT
11/17Insider Sell: Beigene
MT
11/17Insider Sell: Beigene
MT
More news
News in other languages on BEIGENE, LTD.
11/22Beigene présentera les résultats finaux de l'essai Alpine démontrant des Pfs supérieurs..
11/21Beigene, Ltd. annonce le changement du coprésident du comité consultatif scientifique
11/18La Commission européenne approuve le traitement de la leucémie lymphocytaire chronique ..
11/17Mise à jour sectorielle : Les actions du secteur de la santé chu..
11/17BeiGene déclare que la Commission européenne approuve Brukinsa comme traitement de la l..
11/17BeiGene reçoit l'approbation de la Commission européenne pour Brukinsa« (zanubrutinib) ..
11/10Brukinsa de BeiGene décroche les approbations brésiliennes pour certains cancers ; les ..
11/10Beigene, Ltd. Annonce des approbations brésiliennes pour Brukinsa« comme traitement des..
11/09La perte de BeiGene au troisième trimestre se creuse ; les actions chutent de 3 %.
11/09Mise à jour sectorielle : Les actions du secteur de la santé son..
More news
Analyst Recommendations on BEIGENE, LTD.
11/10SVB Securities Adjusts Price Target on BeiGene to $210 From $200, Maintains Outperform ..
MT
11/10Nomura Adjusts BeiGene Price Target to $281.78 From $286.31, Maintains Buy Rating
MT
11/10Nomura Adjusts Beigene's Price Target to HK$170.15 From HK$172.89, Keeps at Buy
MT
10/13Morgan Stanley Raises BeiGene's Price Target to $295 From $290, Maintains Overweight Ra..
MT
10/13Guggenheim Upgrades BeiGene to Buy From Neutral; Price Target is $205
MT
More recommendations
Press releases
11/23BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
AQ
11/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/22BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
BU
11/18BeiGene Receives European Commission Approval for BRUKINSA for the Treatment of Adults ..
AQ
11/17BeiGene Receives European Commission Approval for BRUKINSA« (zanubrutinib) for the Trea..
BU
More press releases